Treatment After Palbociclib-containing Regimens

Fudan University200 enrolled

Overview

To evaluate the prescription patterns and treatment outcomes of subsequent therapies after progression on palbociclib in the real world.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. woman, age \> 18 years old 2. Diagnosed with HR+/HER2- Metastatic Breast Cancer 3. Patients received at least one-cycle next-line treatment after progression on combined palbociclib and endocrine therapy 4. Complete medical history was available Exclusion Criteria: 1\. Medical history was incomplete

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

PFS

Progression free survival

Time frame: 6 weeks

Adverse events

Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.